Advanced Viral Research Corp. Begins Phase II Dermatological Study

YONKERS, N.Y.--(BUSINESS WIRE)--Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) a bio-pharmaceutical company, announced today that the Company has begun a Phase II study using a topically applied spray formulation of AVR 118 as a wound healing agent. Based upon the preliminary results previously seen in an animal model at the University of Miami, this study is designed to determine if a similar response can be demonstrated in humans. The study population will be divided into two cohorts of patients who will undergo a one week course of therapy.